Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study

Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

(2015) K. Yamamoto et al.   JOURNAL OF RHEUMATOLOGY

Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis:post hoctime-course analysis of an all-case PMS in Japan

(2015) Hisashi Yamanaka et al.   Modern Rheumatology

Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis

(2015) Felicity Buckley et al.   Journal of Managed Care & Specialty Pharmacy

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

(2014) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

(2014) Ryuji Koike et al.   Modern Rheumatology

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan

(2013) T. Koike et al.   JOURNAL OF RHEUMATOLOGY

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients

(2013) Takao Koike et al.   Modern Rheumatology

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs

(2013) Daniel H. Solomon et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

(2012) J E Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

(2011) R. Klaasen et al.   RHEUMATOLOGY

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

(2011) T. Takeuchi et al.   RHEUMATOLOGY

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

(2010) Josef S. Smolen et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan

(2009) T. KOIKE et al.   JOURNAL OF RHEUMATOLOGY

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

(2008) J N Hoes et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET